Virus News and Research

Latest Virus News and Research

University of Washington partners with USAID to better identify and prevent future pandemics

Randy CarnellLaboratory medicine scientists look through the window of equipment used in analyzing virus samples.

6 Oct 2021

UTHSC receives $3.2 million to upgrade the Regional Biocontainment Laboratory

The University of Tennessee Health Science Center has been awarded $3.2 million from the National Institute of Allergy and Infectious Diseases (NIAID) to upgrade the equipment and infrastructure in the UTHSC Regional Biocontainment Laboratory (RBL) on the Memphis campus to enhance the university's research of infectious diseases, including COVID-19.

6 Oct 2021

Autoimmune disease drug helps prevent lung damage, death in mice with SARS-CoV-2 infection

In a new paper, researchers at the University of Illinois Chicago report that a drug approved for treating patients with autoimmune disease helped to prevent lung damage and death in mice infected with the SARS-CoV-2 virus, which causes COVID-19 in humans.

6 Oct 2021

Acute myocarditis extremely rare after COVID mRNA vaccination in adults

Now, a new study published in the journal JAMA Internal Medicine evaluated the incidence of acute myocarditis and clinical outcomes among adults who received the mRNA vaccine in an integrated health care system in the United States.

5 Oct 2021

Research highlights challenges in utilizing Ct data to guide COVID-19 clinical planning

In a new study, a collaboration of researchers from various institutes described the natural history of SARS-CoV-2 testing, which includes Ct values among patients who had tested positive multiple times, prior to the emergence of VOCs in the vaccine roll-out. In addition, the authors analyze the timescale of positivity and clinical features of the population of patients with prolonged SARS-CoV-2 positivity.

5 Oct 2021

SARS-CoV-2 variants of concern more virulent than the native strain of the virus

A large study from Ontario confirms that SARS-CoV-2 variants of concern (VOCs), especially the Delta variant, are more virulent than the native strain of the virus, increasing people's risk of hospitalization, admission to the intensive care unit (ICU) and death due to COVID-19.

5 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

COVID-19 survivors under 40 more likely to recover from smell and taste loss, study finds

Sense of smell or taste returns within six months for 4 out of every 5 COVID-19 survivors who have lost these senses, and those under 40 are more likely to recover these senses than older adults, an ongoing Virginia Commonwealth University study found.

5 Oct 2021

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.

5 Oct 2021

A possible protective genetic polymorphism in COVID-19

A new study discusses the role of a mucin gene enhancer on the clinical phenotype of the COVID-19.

5 Oct 2021

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

A new study shows that up to a third of survivors in LTCFs were infected during the first year after infection.

5 Oct 2021

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

One recent study assessed the serum of Beta variant infected patients to determine whether major non-VOC antibodies could neutralize this virus.

5 Oct 2021

Emergence and evolution of endemic and emerging coronavirus diversity in humans and animals

A study aimed to understand the evolutionary and epidemiology dynamics of coronavirus diversity in animals, humans, and wildlife at ecosystem interfaces.

5 Oct 2021

Connection between aerosol transmission and COVID-19 dynamics

A simulation study explored event-level overdispersion of SARS-Cov-2 spread, utilizing real-world inputs from a large number of social gatherings.

5 Oct 2021

The role of ZBP1 in promoting SARS-CoV-2-induced cytokine expression

A new study reported that the ZBP1-induced inflammatory signaling pathway is dependent on ubiquitination and RIPK3’s scaffolding ability, independent of cell death.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Study assesses Texas nurses' COVID-19 vaccination status, intention, and hesitancy

New research focused on Texas nurses has found predictors of a lack of intention to be vaccinated against COVID-19 includes previous COVID-19 infection, unfavorable vaccine attitudes, and concerns about vaccine safety.

5 Oct 2021

UD chemical engineer aims to improve the delivery of therapeutic medicines to the body

The human body has built-in protections to keep pathogens out. That sneezing fit or stuffy nose when you have a cold? That's your body leveraging mucosal linings in your respiratory system to expel the offending virus.

5 Oct 2021

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Researchers from the US recently characterized the scale and specificity of SARS-CoV-2 spike-reactive antibodies from 23 participants who received SARS-CoV-2 mRNA vaccines and 10 acutely infected health care workers. They found that primary mRNA vaccination and infection elicited S1- and S2-reactive antibodies, while secondary mRNA vaccination elicited mostly S1 antibodies.

4 Oct 2021

Virus News and Research

Latest Virus News and Research

University of Washington partners with USAID to better identify and prevent future pandemics

UTHSC receives $3.2 million to upgrade the Regional Biocontainment Laboratory

Autoimmune disease drug helps prevent lung damage, death in mice with SARS-CoV-2 infection

Acute myocarditis extremely rare after COVID mRNA vaccination in adults

Research highlights challenges in utilizing Ct data to guide COVID-19 clinical planning

SARS-CoV-2 variants of concern more virulent than the native strain of the virus

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

COVID-19 survivors under 40 more likely to recover from smell and taste loss, study finds

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A possible protective genetic polymorphism in COVID-19

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

Emergence and evolution of endemic and emerging coronavirus diversity in humans and animals

Connection between aerosol transmission and COVID-19 dynamics

The role of ZBP1 in promoting SARS-CoV-2-induced cytokine expression

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Study assesses Texas nurses' COVID-19 vaccination status, intention, and hesitancy

UD chemical engineer aims to improve the delivery of therapeutic medicines to the body

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in